NRG announces £16m Series A for IND for Parkinson’s and ALS
pharmaphorum
NOVEMBER 9, 2022
A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. Inhibition of the mPTP has been shown, however, to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models.
52 
Let's personalize your content